Skip to main content

Table 2 Baseline characteristics correlated with sustained remission

From: Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab

Variable

Sustained remission (n = 39)

No sustained remission (n = 83)

P value

Female, n (%)

34 (87.2)

65 (78.3)

0.24

Age, years

50.3 ± 18.8 (53.0)

60.1 ± 14.0 (62.0)

0.0067

Weight, kg

52.9 ± 9.1 (51.5)

54.2 ± 11.2 (53.0)

0.70

Disease duration, years

4.9 ± 7.2 (1.8)

9.8 ± 10.0 (7.0)

0.0061

DAS28-ESR at baseline

4.12 ± 0.88 (4.09)

4.68 ± 1.37 (4.48)

0.014

RF-positive, n (%)

25 (64.1)

59 (71.1)

0.44

ACPA-positive, n (%)

26 (72.2)

51 (73.9)

0.85

Presence of bone erosion, n (%)

26 (68.4)

63 (77.8)

0.27

HAQ-DI at baseline

0.63 ± 0.69 (0.38)

1.16 ± 0.82 (1.00)

0.0009

MTX use, n (%)

38 (97.4)

63 (75.9)

0.0033

Oral steroid use, n (%)

6 (15.4)

30 (36.1)

0.019

Prior use of biologics, n (%)

3 (7.7)

32 (38.6)

0.0004

  1. Data are mean ± SD (median) unless otherwise indicated
  2. DAS disease activity score, ESR erythrocyte sedimentation rate, RF rheumatoid factor, ACPA anti-citrullinated protein antibody, HAQ-DI Health Assessment Questionnaire Disability Index, MTX methotrexate